BRAF activates PAX3 to control muscle precursor cell migration during forelimb muscle development

Abstract

Migration of skeletal muscle precursor cells is a key step during limb muscle development and depends on the activity of PAX3 and MET. Here, we demonstrate that BRAF serves a crucial function in formation of limb skeletal muscles during mouse embryogenesis downstream of MET and acts as a potent inducer of myoblast cell migration. We found that a fraction of BRAF accumulates in the nucleus after activation and endosomal transport to a perinuclear position. Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3. Mutation of BRAF dependent phosphorylation sites in PAX3 impaired the ability of PAX3 to promote migration of C2C12 myoblasts indicating that BRAF directly activates PAX3. Since PAX3 stimulates transcription of the Met gene we propose that MET signaling via BRAF fuels a positive feedback loop, which maintains high levels of PAX3 and MET activity required for limb muscle precursor cell migration.

Article and author information

Author details

  1. Jaeyoung Shin

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Shuichi Watanabe

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Soraya Hoelper

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Marcus Krüger

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Sawa Kostin

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1594-9476
  6. Jochen Pöling

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Thomas Kubin

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    For correspondence
    thomas.kubin@mpi-bn.mpg.de
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas Braun

    Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
    For correspondence
    thomas.braun@mpi-bn.mpg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6165-4804

Funding

Deutsche Forschungsgemeinschaft (SFB TRR81 TP02)

  • Thomas Braun

LOEWE Center for Cell and Gene Therapy

  • Thomas Braun

German Center for Cardiovascular Research

  • Thomas Braun

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Margaret Buckingham, Institut Pasteur, France

Ethics

Animal experimentation: All procedures involving animals and their care were carried out in accordance with the guidelines for animal experiments at the Max-Planck-Institute for Heart and Lung Research, which conform to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and the European Parliament Directive 2010/63/EU and the 22 September 2010 Council on the protection of animals. Animal experimentation was approved by the local Ethics committee for animal experiments at the Regierungspräsidium Darmstadt (Registration # B2/1015 „Herstellung transgener Mauslinien; Inaktivierung und Überexpression von Genen"). The animal house at the MPI-HLR is registered according to {section sign}11 German Animal Welfare Law.

Version history

  1. Received: May 31, 2016
  2. Accepted: November 30, 2016
  3. Accepted Manuscript published: December 1, 2016 (version 1)
  4. Version of Record published: December 8, 2016 (version 2)

Copyright

© 2016, Shin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,430
    views
  • 336
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jaeyoung Shin
  2. Shuichi Watanabe
  3. Soraya Hoelper
  4. Marcus Krüger
  5. Sawa Kostin
  6. Jochen Pöling
  7. Thomas Kubin
  8. Thomas Braun
(2016)
BRAF activates PAX3 to control muscle precursor cell migration during forelimb muscle development
eLife 5:e18351.
https://doi.org/10.7554/eLife.18351

Share this article

https://doi.org/10.7554/eLife.18351

Further reading

    1. Cancer Biology
    2. Cell Biology
    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.